selling semaglutide Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s Novo Nordisk sues spas and

While this was no doubt an exciting breakthrough for type-2 diabetes treatments, what has catapulted them front and center is their ability to aid in weight loss

What has happened: its pivotal Phase 3 obesity trial, TRIUMPH-1, reported topline results on May 21, 2026 (28.3% average weight loss at 80 weeks) and is now marked complete on ClinicalTrials.gov

Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes

The prescribing clinician should conduct a thorough baseline assessment of neurological history and maintain appropriate monitoring throughout treatment, adjusting the dose escalation schedule if tolerability issues arise

However, its crucial to recognize that individual results can vary, and continued medical oversight is necessary to adjust treatment plans as needed to support long-term weight management goals